Schematic illustration of MVMαCD3chDC preparation and the therapeutic mechanism. A Schematic of anti-CD3 antibodies-engineered chDC-derived microvesicle mimetic (MVMαCD3chDC) preparation. B MVMαCD3chDC were highly efficiently distributed in spleen and LNs after intravenously injection through the homing ability of MV and the active targeting function of anti-CD3 antibodies on surface. MVMαCD3chDC upregulated the proportion of Treg by delivering microRNA-155-3p and other cargos and promoted immune tolerance in acute inflammatory model and autoimmune disease, which also inhibited the pro-inflammatory M1 macrophages and improved anti-inflammatory M2 macrophages